Pluri

Company Overview

Snapshot

Founded in January 2003, Pluri operates with 201–500 employees and has raised a total of $139.4M across 14 funding rounds from 4 investors. The company went public on NASDAQ in April 2003.

Business overview

Pluri develops cell-based products for commercial applications, focusing on global well-being and sustainability. The company's core technology is a patented and validated 3D cell expansion system that facilitates novel cell-based solutions across various initiatives, including medicine, climate change, food scarcity, and animal welfare. Pluri currently operates in regenerative medicine and food technology, seeking partnerships to leverage its 3D cell-based technology for mass cell production in additional industries. It primarily serves the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals and Biotechnology.

Strategic signal

In October 2025, Pluri's subsidiary Coffeesai partnered with Mexico’s Instituto del Café de Chiapas (INCAFECH) to advance cell-based coffee manufacturing. This collaboration signals Pluri's strategic expansion beyond traditional regenerative medicine into sustainable food technology, demonstrating the versatility of its 3D cell expansion platform and its commitment to addressing global challenges like food scarcity through innovative biotech applications. This move could open significant new market opportunities for the company.

Company Intelligence Q&A

What is Pluri's primary focus in the food technology sector?

Pluri's subsidiary Coffeesai is focused on advancing cell-based coffee manufacturing, as evidenced by its strategic collaboration with Mexico’s Instituto del Café de Chiapas announced in October 2025.

What significant partnership did Pluri establish in November 2024?

In November 2024, Pluri partnered with BrainStorm Cell Therapeutics to support the manufacturing for the NurOwn® Phase 3b trial, indicating its involvement in advanced cellular therapies for neurodegenerative diseases.

What was a key strategic announcement from Pluri's CEO in May 2025?

In May 2025, Pluri's CEO issued a shareholder letter highlighting strategic growth, innovation, and global market expansion, underscoring the company's forward-looking business strategy.

What was Pluri's financial performance in the first quarter of 2025?

Pluri reported a US$1.08 loss per share in its First Quarter 2025 Earnings, as announced in November 2024.

What was a notable collaboration for Pluri in May 2024?

In May 2024, Pluri collaborated with Wilk to develop human breast milk-derived food production on a commercial scale, aiming to create a novel medical food solution for the elderly.